PLX

Protalix is a genuine commercial-stage rare-disease player, not a pre-revenue story: FY2025 revenue was $52.7M, split across Elfabrio (Chiesi, $22.5M) and Elelyso (Pfizer $18.2M + Brazil MoH $11.1M). That diversification and a clean-ish balance sheet — $48.2M equity, liabilities/equity of just 0.71x — put a floor under the name that most micro-cap biotechs lack, and at $2.32 the 3.5x P/S is not demanding. But the trend turned the wrong way. Revenue is flat-to-declining (-1.2% YoY, and down from the FY2023 peak of $65.5M), and the company swung from +$2.93M net income in FY2024 to a -$6.60M loss in FY2025 (EPS -$0.08), with operating income at -$5.5M. The loss is largely self-inflicted growth spend — R&D jumped 50.9% to $19.6M as management pivots 'focus to new, early-stage product candidates' and funds the PRX-115 Phase 2 RELEASE gout trial.

The hard constraint is the cash box. Operating cash flow was -$12.0M and cash fell 25.7% to $14.7M — roughly a single year of runway at the current burn. The 10-K's own risk factors flag it plainly ('We may need to raise additional capital... which may not be available on favorable terms, or at all'), and the disclosed At-The-Market offering agreement is the likely funding valve, meaning near-term dilution on top of the 3.3% share-count creep already booked. Layer on the structural risks the filing stresses: heavy dependence on Elfabrio and Elelyso, reliance on Chiesi/Pfizer as the commercial channel and on third parties for final processing, and Israel-based operations exposed to 'military, political and economic conditions.'